An Introduction to Insulin Use in Type 2 Diabetes Mellitus

Overview

Journal S Afr Fam Pract (2004)

Specialties General Medicine
Public Health

Date 2023 May 3

PMID 37132569

Authors

Ankia Coetzee

Affiliations

Soon will be listed here.

Abstract

The benefits of the newer antidiabetic agents available for managing type 2 diabetes mellitus (T2DM) remain indisputable, but many patients will require insulin therapy in the disease course. Given the limited access to newer antidiabetic agents, insulin remains a standard treatment modality in T2DM in South Africa. Early, multifactorial intervention remains ideal, but glucose, blood pressure and cholesterol values remain above target in many countries. Barriers to achieving glucose control in South Africa include the healthcare provider's being unfamiliar with the practicalities of insulin administration, initiation and titration. This article highlights these gaps and offers pragmatic solutions to overcome them.

References

. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2021; 45(Suppl 1):S144-S174. DOI: 10.2337/dc22-S010. View

Abdul-Ghani M, DeFronzo R . Personalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?. Expert Opin Pharmacother. 2021; 22(16):2113-2125. DOI: 10.1080/14656566.2021.1967319. View

Janka H, Plewe G, Riddle M, Kliebe-Frisch C, Schweitzer M, Yki-Jarvinen H . Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005; 28(2):254-9. DOI: 10.2337/diacare.28.2.254. View

Ichikawa M, Akiyama T, Tsujimoto Y, Anan K, Yamakawa T, Terauchi Y . Efficacy of education on injection technique for patients diagnosed with diabetes with lipohypertrophy: systematic review and meta-analysis. BMJ Open. 2022; 12(3):e055529. PMC: 8905878. DOI: 10.1136/bmjopen-2021-055529. View

Wu T, Betty B, Downie M, Khanolkar M, Kilov G, Orr-Walker B . Practical Guidance on the Use of Premix Insulin Analogs in Initiating, Intensifying, or Switching Insulin Regimens in Type 2 Diabetes. Diabetes Ther. 2015; 6(3):273-87. PMC: 4575300. DOI: 10.1007/s13300-015-0116-0. View

Raccah D . Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitus. Diabetes Obes Metab. 2008; 10 Suppl 2:76-82. DOI: 10.1111/j.1463-1326.2008.00846.x. View

Basu A, Basu R . Insulin:Carbohydrate Ratio--Part of the Story. Diabetes Technol Ther. 2015; 17(12):851-3. PMC: 4677107. DOI: 10.1089/dia.2015.0333. View

Radziuk J, Pye S . Diurnal rhythm in endogenous glucose production is a major contributor to fasting hyperglycaemia in type 2 diabetes. Suprachiasmatic deficit or limit cycle behaviour?. Diabetologia. 2006; 49(7):1619-28. DOI: 10.1007/s00125-006-0273-9. View

Robertson R, Harmon J, Tran P, Poitout V . Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes. 2004; 53 Suppl 1:S119-24. DOI: 10.2337/diabetes.53.2007.s119. View

10.

Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A . Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care. 2005; 28(4):950-5. DOI: 10.2337/diacare.28.4.950. View

11.

Marx N, Davies M, Grant P, Mathieu C, Petrie J, Cosentino F . Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. Lancet Diabetes Endocrinol. 2020; 9(1):46-52. DOI: 10.1016/S2213-8587(20)30343-0. View

12.

Webb E, Rheeder P, Van Zyl D . Diabetes care and complications in primary care in the Tshwane district of South Africa. Prim Care Diabetes. 2014; 9(2):147-54. DOI: 10.1016/j.pcd.2014.05.002. View

13.

Woerle H, Meyer C, Dostou J, Gosmanov N, Islam N, Popa E . Pathways for glucose disposal after meal ingestion in humans. Am J Physiol Endocrinol Metab. 2002; 284(4):E716-25. DOI: 10.1152/ajpendo.00365.2002. View

14.

Jenkins D, Wolever T, Taylor R, Barker H, Fielden H, Baldwin J . Glycemic index of foods: a physiological basis for carbohydrate exchange. Am J Clin Nutr. 1981; 34(3):362-6. DOI: 10.1093/ajcn/34.3.362. View

15.

Del Prato S, Tiengo A . The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus. Diabetes Metab Res Rev. 2001; 17(3):164-74. DOI: 10.1002/dmrr.198. View

16.

Blonde L, Merilainen M, Karwe V, Raskin P . Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study. Diabetes Obes Metab. 2009; 11(6):623-31. DOI: 10.1111/j.1463-1326.2009.01060.x. View

17.

Holman R, Thorne K, Farmer A, Davies M, Keenan J, Paul S . Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007; 357(17):1716-30. DOI: 10.1056/NEJMoa075392. View

18.

. 2. Classification and Diagnosis of Diabetes: . Diabetes Care. 2019; 43(Suppl 1):S14-S31. DOI: 10.2337/dc20-S002. View

19.

Mohan V, Saboo B, Khader J, Modi K, Jindal S, Wangnoo S . Position of Sulfonylureas in the Current ERA: Review of National and International Guidelines. Clin Med Insights Endocrinol Diabetes. 2022; 15:11795514221074663. PMC: 8854230. DOI: 10.1177/11795514221074663. View

20.

Christiaens A, Henrard S, Zerah L, Dalleur O, Bourdel-Marchasson I, Boland B . Individualisation of glycaemic management in older people with type 2 diabetes: a systematic review of clinical practice guidelines recommendations. Age Ageing. 2021; 50(6):1935-1942. DOI: 10.1093/ageing/afab157. View